Edwards Lifesciences Corp (EW) Shares Sold by Marino Stram & Associates LLC

Share on StockTwits

Marino Stram & Associates LLC decreased its position in Edwards Lifesciences Corp (NYSE:EW) by 46.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 700 shares of the medical research company’s stock after selling 600 shares during the quarter. Marino Stram & Associates LLC’s holdings in Edwards Lifesciences were worth $102,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EW. Daiwa Securities Group Inc. increased its position in shares of Edwards Lifesciences by 9.1% during the first quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock worth $961,000 after acquiring an additional 572 shares during the period. Atria Investments LLC grew its stake in shares of Edwards Lifesciences by 18.9% during the first quarter. Atria Investments LLC now owns 4,287 shares of the medical research company’s stock worth $598,000 after purchasing an additional 680 shares in the last quarter. Mackay Shields LLC acquired a new position in shares of Edwards Lifesciences during the first quarter worth $4,970,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Edwards Lifesciences by 2.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,656 shares of the medical research company’s stock worth $6,509,000 after purchasing an additional 981 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Edwards Lifesciences by 0.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 2,039,834 shares of the medical research company’s stock worth $284,599,000 after purchasing an additional 5,466 shares in the last quarter. 82.12% of the stock is currently owned by institutional investors.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,500 shares of the company’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $150.00, for a total value of $825,000.00. Following the completion of the transaction, the vice president now owns 25,512 shares in the company, valued at $3,826,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Larry L. Wood sold 6,300 shares of the company’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $151.86, for a total transaction of $956,718.00. The disclosure for this sale can be found here. Insiders sold 122,075 shares of company stock valued at $17,626,656 in the last 90 days. 1.84% of the stock is currently owned by insiders.

NYSE EW opened at $140.55 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. Edwards Lifesciences Corp has a 1 year low of $100.20 and a 1 year high of $156.87. The firm has a market capitalization of $29.27 billion, a price-to-earnings ratio of 36.99, a P/E/G ratio of 1.93 and a beta of 0.57.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. During the same quarter in the prior year, the firm posted $1.08 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 10.0% on a year-over-year basis. sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. Northland Securities reiterated a “hold” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research note on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and set a $168.00 target price on shares of Edwards Lifesciences in a research note on Friday, July 27th. Sanford C. Bernstein assumed coverage on shares of Edwards Lifesciences in a research note on Wednesday, June 27th. They set a “market perform” rating and a $165.00 target price for the company. Finally, ValuEngine upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Tuesday, June 12th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Edwards Lifesciences presently has an average rating of “Buy” and an average price target of $152.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: What is a Fiduciary?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply